PURPOSE:Sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor approved for the treatment of type 2 diabetes, is reported to be more efficacious in Indian patients than non-Indian patient population. The objective of the study was to evaluate pharmacokinetic and pharmacodynamic (PK/PD) parameters of single-dose sitagliptin 100 mg (Januvia) in healthy Indian male participants. METHOD: In a randomised, single-dose, open-label, three-treatment, three-period, three-sequence, crossover bioavailability study, 18 healthy male participants receivedsingle-dose of sitagliptin under fasted and fed conditions. PK parameters (Cmax, Tmax, AUC0-∞ and t1/2) were determined using Phoenix WinNonlin software. PD parameters [DPP-IV inhibition, active glucagon-like peptide-1 (GLP-1) and insulin] were determined using established methods. RESULTS: PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr. The weighted average (WA) plasma DPP-4 inhibition over 24 h was 89.6% and WA of plasma active GLP-1 over 2 h after standardised meal (geometric mean ratio) was 11.1 (9.9) pM/L which is two- to- four fold higher compared to that reported in other populations. The mean average (SD) AUC of plasma insulin over 2 h of standardised meal was 47.9 (24.9) μIU/mL. CONCLUSION: Although, there are differences in pharmacokinetic parameters, no clinically meaningful differences were observed with respect to DPP-IV inhibition between Indian and non-Indian population.
RCT Entities:
PURPOSE:Sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor approved for the treatment of type 2 diabetes, is reported to be more efficacious in Indian patients than non-Indian patient population. The objective of the study was to evaluate pharmacokinetic and pharmacodynamic (PK/PD) parameters of single-dose sitagliptin 100 mg (Januvia) in healthy Indian male participants. METHOD: In a randomised, single-dose, open-label, three-treatment, three-period, three-sequence, crossover bioavailability study, 18 healthy male participants received single-dose of sitagliptin under fasted and fed conditions. PK parameters (Cmax, Tmax, AUC0-∞ and t1/2) were determined using Phoenix WinNonlin software. PD parameters [DPP-IV inhibition, active glucagon-like peptide-1 (GLP-1) and insulin] were determined using established methods. RESULTS: PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr. The weighted average (WA) plasma DPP-4 inhibition over 24 h was 89.6% and WA of plasma active GLP-1 over 2 h after standardised meal (geometric mean ratio) was 11.1 (9.9) pM/L which is two- to- four fold higher compared to that reported in other populations. The mean average (SD) AUC of plasma insulin over 2 h of standardised meal was 47.9 (24.9) μIU/mL. CONCLUSION: Although, there are differences in pharmacokinetic parameters, no clinically meaningful differences were observed with respect to DPP-IV inhibition between Indian and non-Indian population.
Authors: Gary A Herman; Goutam C Mistry; Bingming Yi; Arthur J Bergman; Amy Q Wang; Wei Zeng; Li Chen; Karen Snyder; Jon L Ruckle; Patrick J Larson; Michael J Davies; Ronald B Langdon; Keith M Gottesdiener; John A Wagner Journal: Br J Clin Pharmacol Date: 2011-03 Impact factor: 4.335
Authors: Ganesh V Sangle; Lina M Lauffer; Anthony Grieco; Shivangi Trivedi; Roman Iakoubov; Patricia L Brubaker Journal: Endocrinology Date: 2011-12-20 Impact factor: 4.736
Authors: Arun K P; Venkata Subbaiah Meda; V S P Raj Kucherlapati; Anil Dubala; Deepalakshmi M; Anand VijayaKumar P R; Elango K; Suresh B Journal: Eur J Clin Pharmacol Date: 2011-12-16 Impact factor: 2.953
Authors: Debora Williams-Herman; Jeremy Johnson; Rujun Teng; Edmund Luo; Michael J Davies; Keith D Kaufman; Barry J Goldstein; John M Amatruda Journal: Curr Med Res Opin Date: 2009-03 Impact factor: 2.580
Authors: A Ramachandran; C Snehalatha; S Mary; S Selvam; C K S Kumar; A C Seeli; A S Shetty Journal: Diabetologia Date: 2009-03-10 Impact factor: 10.122
Authors: Viswanathan Mohan; Wenying Yang; Ho-Young Son; Lei Xu; Liliane Noble; Ronald B Langdon; John M Amatruda; Peter P Stein; Keith D Kaufman Journal: Diabetes Res Clin Pract Date: 2008-12-20 Impact factor: 5.602